XLO (Xilio Therapeutics) OCF Margin %: -176.65% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XLO Xilio Therapeutics Inc XLO
32 GF Score
Price $8.64
! 2 Warning Signs
View Full Analysis

What is Xilio Therapeutics OCF Margin %?

Xilio Therapeutics XLO +1.05% 32 OCF Margin % is -176.65% as of Mar. 2026. GuruFocus rates XLO with a GF Score™ of 32/100. The stock has 2 warning signs investors should review. Among 950 Biotechnology companies, Xilio Therapeutics ranks worse than 54.74% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Xilio Therapeutics's Cash Flow from Operations for the three months ended in Mar. 2026 was $-22.34 Mil. Xilio Therapeutics's Revenue for the three months ended in Mar. 2026 was $12.65 Mil. Therefore, Xilio Therapeutics's OCF Margin % for the quarter that ended in Mar. 2026 was -176.65%.

As of today, Xilio Therapeutics's current OCF Yield % is -99.13%.

The historical rank and industry rank for Xilio Therapeutics's OCF Margin % or its related term are showing as below:

XLO' s OCF Margin % Range Over the Past 10 Years
Min: -289.69   Med: -150.55   Max: -11.41
Current: -105.29

During the past 7 years, the highest OCF Margin % of Xilio Therapeutics was -11.41%. The lowest was -289.69%. And the median was -150.55%.

XLO's OCF Margin % is ranked worse than
54.74% of 950 companies
in the Biotechnology industry
Industry Median: -65.71 vs XLO: -105.29

Xilio Therapeutics OCF Margin % Related Terms

Xilio Therapeutics OCF Margin % Historical Data

* Premium members only.

The historical data trend for Xilio Therapeutics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xilio Therapeutics OCF Margin % Chart

Xilio Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 -289.69 -11.41

Xilio Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 989.01 -179.08 -91.76 -14.60 -176.65

XLO vs FLNA, BSEM, BOLD: OCF Margin % Comparison

For the Biotechnology subindustry, Xilio Therapeutics's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xilio Therapeutics OCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xilio Therapeutics's OCF Margin % distribution charts can be found below:

* The bar in red indicates where Xilio Therapeutics's OCF Margin % falls into.


XLO
32GF Score
Xilio Therapeutics Inc XLO
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xilio Therapeutics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Xilio Therapeutics's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-4.992/43.766
=-11.41 %

Xilio Therapeutics's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-22.343/12.648
=-176.65 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of -176.65% mean?
Xilio Therapeutics (XLO) has a OCF Margin % of -176.65% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Xilio Therapeutics and its competitors. According to the industry distribution chart, Xilio Therapeutics ranks #520 out of 950 companies in the Biotechnology industry, placing it in the top 54.7%.
Is Xilio Therapeutics' OCF Margin % too high?
Xilio Therapeutics' current OCF Margin % is -176.65%. Based on the distribution chart, Xilio Therapeutics ranks #520 out of 950 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Xilio Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Xilio Therapeutics' OCF Margin % compare to FLNA and BSEM?
According to the Biotechnology industry distribution chart, Xilio Therapeutics ranks #520 out of 950 companies for OCF Margin %. This places Xilio Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Xilio Therapeutics and its competitors. Xilio Therapeutics's current OCF Margin % is -176.65%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xilio Therapeutics stock overvalued right now?
Xilio Therapeutics (XLO) has a current OCF Margin % of -176.65%. The current OCF Margin % is -176.65%. Xilio Therapeutics' overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Xilio Therapeutics (XLO), the current OCF Margin % is -176.65% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Xilio Therapeutics Business Description

Address 828 Winter Street, Suite 300, Waltham, MA, USA, 02451
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.
32GF Score

Get the complete analysis for XLO

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.64
Price